Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330313 | 0.77 | FPR3 (0.38) | KMT2AMEN1HCAR2CNR1MME | |
| SCHEMBL1260411 | 0.75 | CNR1 (0.43) | KMT2ACNR1 | |
| SCHEMBL1259808 | 0.70 | PTGES (0.36) | CNR1 | |
| SCHEMBL3136472 | 0.67 | CNR1 (0.45) | CNR1CDK2PIN1 | |
| SCHEMBL22321660 | 0.67 | PIN1 (0.51) | MMEPIN1 | |
| SCHEMBL1259826 | 0.66 | CYP2C9 (0.42) | CNR1 | |
| SCHEMBL10283715 | 0.66 | CTRB1 (0.52) | MMEPIN1 | |
| SCHEMBL13285960 | 0.66 | CTRB1 (0.52) | MMEPIN1 | |
| SCHEMBL12115589 | 0.66 | ACACB (0.60) | KMT2AMEN1PIN1 | |
| SCHEMBL16211796 | 0.66 | ITGA4 (0.47) | CNR1MMECDK2ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | claimed |
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-14 | — | — | US | claimed |
| US-7381727-B2 | Pyrrole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-03 | — | — | US | claimed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | claimed |
| EP-1781636-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2007-05-09 | — | — | EP | claimed |
| WO-2006024777-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | WO | claimed |
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-14 | — | — | US | disclosed |
| US-7381727-B2 | Pyrrole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-03 | — | — | US | disclosed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
| EP-1781636-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006024777-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | PYCR1, FARS2, WEE1 | KMT2A 3880/4885MEN1 1207/4885HCAR2 606/4885 |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PYCR1, PRMT9, PRLHR | KMT2A 3477/4885MEN1 2567/4885HCAR2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.